# A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Source: https://onco.cc/trials/nct07154264/  
OnCo record `nct07154264` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of DZD8586 and Venetoclax in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.

## Summary

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) is a phase 2 interventional study registered as NCT07154264 by Dizal Pharmaceuticals, with 66 participants planned, started 2025-09-22 and due to reach its primary completion in 2029-12. Interventions recorded: DZD8586 and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07154264
- Phase: 2
- Setting: A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
- Sponsor: Dizal Pharmaceuticals
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT07154264: https://clinicaltrials.gov/study/NCT07154264

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [DZD8586](https://onco.cc/drugs/dzd8586/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)

---
JSON: https://onco.cc/api/v1/entities/nct07154264.json